AMPLIFICATION AND OVEREXPRESSION OF THE PSMB5 GENE CONTRIBUTE TO BORTEZOMIB RESISTANCE IN RE-TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

被引：0
|
作者：
Altavilla, Giuseppe [1 ]
Arrigo, Carmela [1 ]
Sauta, Maria Grazia [1 ]
Galletti, Giuseppe [1 ]
Gnani, Alessandro [1 ]
Pettineo, Giuseppe [1 ]
Buemi, Barbara [1 ]
Pitini, Vincenzo [1 ]
机构：
[1] Univ Messina, Human Pathol Dpt, Med Oncol Unit, I-98100 Messina, Italy
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 43 条
  • [21] BORTEZOMIB RE-TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (MM). A REAL WORLD MEDICAL PRACTICE EXPERIENCE FROM A SWEDISH NATIONAL REGISTRY
    Thilakarathne, P.
    Diels, J.
    van Sanden, S.
    Liwing, J.
    Chirita, O.
    Van Agthoven, M.
    Nahi, H.
    VALUE IN HEALTH, 2014, 17 (07) : A617 - A617
  • [22] Efficacy and Safety of Re-Treatment with Bortezomib (Velcade©) in Patients with Multiple Myeloma: Results from a Prospective International Phase II Trial.
    Petrucci, Maria Teresa
    Blau, Igor W.
    Corradini, Paolo
    Dimopoulos, Meletios A.
    Drach, Johannes
    Giraldo, Pilar
    Teixeira, Adriana
    Blade, Joan
    BLOOD, 2008, 112 (11) : 1264 - 1264
  • [23] Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
    Plakoula, Eva
    Kalampounias, Georgios
    Alexis, Spyridon
    Verigou, Evgenia
    Kourakli, Alexandra
    Zafeiropoulou, Kalliopi
    Symeonidis, Argiris
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2025, 47 (01)
  • [24] The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene
    Franke, Niels E.
    van Meerloo, Johan
    Slot, Linda
    Li, Xiaoming
    Wood, Tabitha E.
    Vojtekova, Katarina
    Verbrugge, Sue Ellen
    Kaspers, Gertjan
    Batey, Robert A.
    Schimmer, Aaron D.
    Jansen, Gerrit
    Cloos, Jacqueline
    BLOOD, 2009, 114 (22) : 388 - 388
  • [25] Bortezomib-Dexamethasone Re-Treatment at Biochemical Relapse Vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II Multi-Center, Randomized Study
    Mina, Roberto
    Larocca, Alessandra
    Belotti, Angelo
    Di Raimondo, Francesco
    Baraldi, Anna
    Offidani, Massimo
    Marchetti, Monia
    Ria, Roberto
    Conconi, Annarita
    Pescosta, Norbert
    Grasso, Mariella
    Cetani, Giusy
    Cafro, Anna Maria
    Passera, Roberto
    Troia, Rossella
    Semenzato, Gianpietro
    Giuliani, Nicola
    Ballanti, Stelvio
    Cellini, Claudia
    Liberati, Anna Marina
    Di Toritto, Tommaso Caravita
    Petrucci, Maria Teresa
    Musto, Pellegrino
    Palumbo, Antonio
    Sonneveld, Pieter
    Boccadoro, Mario
    BLOOD, 2017, 130
  • [26] Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma
    Tokuhira, Michihide
    Watanabe, Reiko
    Nemoto, Tomoe
    Hanzawa, Kyoko
    Sagawa, Morihiko
    Tomikawa, Takeshi
    Mori, Shigehisa
    Kizaki, Masahiro
    LEUKEMIA RESEARCH, 2011, 35 (05) : 591 - 597
  • [27] Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record
    Bernardeschi, Paolo
    Pirrotta, Maria Teresa
    Montenora, Iolanda
    Giustarini, Gloria
    Ferreri, Maria Immacolata
    Simi, Paolo
    Fiorentini, Giammaria
    LEUKEMIA RESEARCH, 2010, 34 (04) : E104 - E105
  • [28] Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse
    Cohen, Oliver C.
    Counsell, Nicholas
    Rabin, Neil
    Popat, Rakesh
    Owen, Roger G.
    Popova, Bilyana
    Schofield, Oliver
    Clifton-Hadley, Laura
    Lyons-Lewis, Janet
    Rawstron, Andy
    Spence, Christopher
    de Tute, Ruth M.
    Hughes, Derralynn
    Moore, Sally
    Smith, Paul
    Yong, Kwee L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 948 - 951
  • [29] Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study
    Mina, Roberto
    Larocca, Alessandra
    Belotti, Angelo
    Conticello, Concetta
    Monaco, Federico
    Offidani, Massimo
    Ronconi, Sonia
    Marchetti, Monia
    Ria, Roberto
    Mosca-Siez, Maria Letizia
    Pescosta, Norbert
    Grasso, Mariella
    Capra, Andrea
    Zambello, Renato
    Poggiu, Marco
    Giuliani, Nicola
    Ballanti, Stelvio
    Cellini, Claudia
    Liberati, Anna Marina
    Siniscalchi, Agostina
    Petrucci, Maria Teresa
    Palumbo, Antonio
    Musto, Pellegrino
    Sonneveld, Pieter
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E271
  • [30] RE-TREATMENT VS CHANGE THERAPY IN FIRST RELAPSE: POST-HOC ANALYSIS OF 476 PATIENTS WITH MULTIPLE MYELOMA (MM) INCLUDED IN TWO PROSPECTIVE TRIALS
    Offidani, M.
    Corvatta, L.
    Bringhen, S.
    Gentili, S.
    Gay, F.
    Maracci, L.
    Ciccone, G.
    Boccadoro, M.
    Leoni, P.
    Palumbo, A.
    HAEMATOLOGICA, 2015, 100 : 511 - 511
12345